| dc.description.abstract | Painful diabetic neuropathy (PDN) is a complication of long-term diabetes mellitus (DM)
characterized by hyperalgesia and allodynia. In streptozotocin (STZ)-induced diabetic
mice, higher dose of STZ and lengthened hyperglycemic condition results in better model
of PDN. However, higher dose of STZ tend to induce mortality. The aim of the study was
to evaluate the doses of STZ that caused PDN with less mortality rate and the timing
of pain behavior development in mice model of PDN. BALB/c mice were divided into
non-diabetic and STZ-induced diabetic group. The doses of STZ were started from 180
mg/kg BW i.p. Serum glucose levels were measured 7 days (one week) after induction.
Mice with glucose levels ≥ 200 mg/dL were considered as diabetic. Pain behaviour was
determined by four method i.e. hot plate, tail flick, von Frey filament and Randall Selitto
tests, measured on week-0 (baseline), 1, 2, 3, 4 and 5. Data were presented as mean
± SEM. The mean differences between weeks were evaluated by One-Way ANOVA and
the mean differences between two groups by independent t-test. STZ doses 180, 150
and 120 mg/kg BW caused 100% death and STZ 90 mg/kg BW failed to induce diabetic
condition. STZ 110 mg/kg BW resulted in 0% mortality while it induced diabetes in 100%
of the mice. Latency time toward thermal stimulus decreased to 5.8 ± 0.4 sec at 1
week after the mice become diabetes (p<0.05) and it was continued to decrease until
4
week. The same result was also showed in tail flick and Randal Selitto tests. The
pain sensitivity determined by von Frey filament decreased to 1.37 ± 0.12 g at 1
th
week
(p<0.05) and continued to decrease until 5
week. In conclusion, optimum dose of STZ
to induce PDN was 110 mg/kg BW. Pain behaviour of diabetic group was observed at 1
th week after diabetes and continued until 5th week. | en_US |
